Skip to content


To access our online store, you must be registered as a patient with Emerald Health Therapeutics and have your Client ID and Password handy. 

⇒ Check out our medical product catalogue below and then sign in to start shopping. 

*Disclaimer: The cannabinoid potencies of our oils are subject to batch variance (+/- 10%) depending on the natural yield of the plant.

All sales are final. No product returns will be accepted, and no exchanges will be available. Please note that our cut-off for weekday orders for shipping is 11:00 a.m. PST. Prices shown are per gram, and potential THC and CBD numbers are for the decarboxylated product.


Explore our high-quality strains, with a selection that offers varying percentages of THC and CBD. With over 60 years of growing experience, we put extra care into growing, drying and curing our cannabis. Every batch is tested in independent labs, ensuring our commitment to both our products and our patients. 

Med SYNC Nano products are fast-action oral sprays that use nanoemulsion technology to achieve faster and more predictable effects. The discreet sublingual spray bottle allows for a high degree of control over the dosage. Designed to work in 15-20 minutes and last between 2-4 hours. Emerald medical fast-action sprays are currently available in a CBD format. 

Our cannabis oils are whole-plant cannabis extracts that deliver the benefits of active cannabinoids and terpenes orally. Our new oil formulations include 100% coconut-derived carrier, as well as naturally flavoured offerings.

We offer a range of pre-rolled cannabis products with a variety of different THC and CBD percentages. Like our other dried cannabis products, pre-rolls are tested in independent labs.


Learn more about Emerald’s whole-flower dried cannabis and SYNC smoke-free products available in the recreational market. 

Rebecca Wong

Vice President, Quality and Regulatory Affairs

Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.


President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.